efsa-opinion-chromium-food-drinking-water

Chromium in food and bottled water
Table H1: Repeated toxicity studies with Cr(III) compounds (continued)
Study* NOAEL LOAEL Effect Reference
2-year oral (diet)
50000 mg/kg - Increased incidence of preputial gland adenoma in NTP (2010)
F: 0, 12, 61, 314 mg Cr(III)/kg b.w. per day (a)
F344/N rats
50M + 50 F/group
0, 2000, 10000 or 50000 mg/kg diet chromium picolinate
monohydrate ( M: 0, 90, 460 or 2400 and F: 0, 100, 510 or
2630 mg chromium picolinate monohydrate/kg b.w. per day)
Doses:
M: 0, 10.7, 55, 286 mg Cr(III)/kg b.w. per day (a)
diet
M: 286 and
F: 314 mg
Cr(III)/kg
b.w. per day
M at 10000 and 50000 ppm (> hist. C range)
(1/50, 1/50, 7/50 and 4/50).
The CONTAM Panel do not consider this benign
lesion to be treatment-related.
2-year oral (diet)
50000 mg/kg - Decrease mean b.w. of 50000 ppm females NTP (2010)
F: 0, 29, 143, 728 mg Cr(III)/kg b.w. per day (a)
B6C3F1 mice
50M + 50 F/group
0, 2000, 10000 or 50000 mg/kg diet chromium picolinate
monohydrate ( M: 0, 250, 1200 or 6565 and F: 0, 240, 1200 or
6100 mg chromium picolinate monohydrate/kg b.w. per day)
Doses:
M: 0, 30, 143, 783 mg Cr(III)/kg b.w. per day (a)
diet
M: 783 and
F: 728 mg
Cr(III)/kg
b.w. per day
(10 %) at 1-year, but similar to control group at 2-
year.
b.w.: body weight; NOAEL: no-observed-adverse-effect level; LOAEL: lowest-observed-adverse-effect level; MW: molecular weight; M: male; F: female.
* In the conversions from concentration to daily doses, the MW of the anhydrous salts were used when no information on hydration number was available in the original publication.
(a): Conversion using the data reported in the original publication.
(b): Conversion using drinking water/feed consumption data and average body weight reported in the publication.
(c): Conversion using the default correction factor for subacute/subchronic/chronic exposure via drinking water/feed from EFSA SC (2012).
EFSA Journal 2014;12(3):3595 187